EVP, Research and Development (11) · Aurinia Pharmaceuticals Inc. (AUPH)

Volker Knappertz

FY2022 is the first fiscal year CompBrief holds for Volker Knappertz as a named executive officer of Aurinia Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$2,983,686

Salary $229,167Stock awards $1,250,002

7th of 7 named executive officers at Aurinia Pharmaceuticals by FY2022 total.

7 named officers on file for Aurinia Pharmaceuticals, FY2022

Volker Knappertz’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • AUPH’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Aurinia Pharmaceuticals’s whole pay program stands against its peers

  • Aurinia Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AUPH→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 18, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Volker Knappertz’s full pay file as a PDF — free

More than this page: up to 10 years of Volker’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Volker Knappertz compensation by year

Aurinia Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Aurinia Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022
Salary$229,167
Bonus$0
Stock awards$1,250,002
Option awards$1,249,337
Non-equity incentive$250,000
Pension and deferred compensation$0
All other$5,180
Total$2,983,686

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aurinia Pharmaceuticals Inc. DEF 14A filed April 18, 2023, accession 0001600620-23-000005, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Aurinia Pharmaceuticals Inc. filed document, accession 0001600620-23-000005. Every figure is read from that document and cited to the page and table it appears in. Filed April 18, 2023.

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
PSU152,812$1,250,002—
Option256,892—$8.18

Per the Outstanding Equity Awards at Fiscal Year-End table in Aurinia Pharmaceuticals Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

2 Form 4 lines since the FY2022 proxy (filed April 18, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2024-02-27Sale—4,930$6.10319,128
2024-02-20Sale—25,146$5.48324,058

The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Aurinia Pharmaceuticals’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Peter GreenleafChief Executive Officer$8,837,397
Max ColaoFormer Chief Commercial Officer (8)$3,603,002
Max DonleyEVP, Operations and Strategy$3,312,497
Joe MillerChief Financial Officer (7)$3,292,594
Stephen RobertsonEVP, General Counsel, Corporate Secretary and Chief Compliance Officer (9)$3,240,355
Neil SolomonsFormer Chief Medical Officer (10)$3,222,128
Volker Knappertz · this pageEVP, Research and Development (11)$2,983,686

The full Aurinia Pharmaceuticals compensation record

free company brief

This page is one person within Aurinia Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Aurinia Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aurinia Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Volker Knappertz's compensation dossier · One-time report. No refunds.